{"Title": "Dimers Aren't Forever: CD80 Breaks up with PD-L1", "Year": 2019, "Source": "Immunity", "Volume": "51", "Issue": 6, "Art.No": null, "PageStart": 972, "PageEnd": 974, "CitedBy": 2, "DOI": "10.1016/j.immuni.2019.11.011", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85076132630&origin=inward", "Abstract": "\u00a9 2019 Elsevier Inc.Targeting the CTLA-4 and PD-1 \u201ccheckpoints\u201d is an effective treatment for a number of cancers. In this issue of Immunity, Hui et al. reveal that interaction between a CTLA-4 ligand, CD80, and its counterpart in the PD-1 pathway, PD-L1, affects both PD-1 and CTLA-4 function, raising new questions about the biological effects of using checkpoint inhibitors alone and in combination.\u00a9 2019 Elsevier Inc.Targeting the CTLA-4 and PD-1 \u201ccheckpoints\u201d is an effective treatment for a number of cancers. In this issue of Immunity, Hui et al. reveal that interaction between a CTLA-4 ligand, CD80, and its counterpart in the PD-1 pathway, PD-L1, affects both PD-1 and CTLA-4 function, raising new questions about the biological effects of using checkpoint inhibitors alone and in combination.", "AuthorKeywords": null, "IndexKeywords": ["B7-1 Antigen", "B7-H1 Antigen", "CD28 Antigens", "CTLA-4 Antigen", "Programmed Cell Death 1 Receptor"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85076132630", "SubjectAreas": [["Immunology and Allergy", "MEDI", "2723"], ["Immunology", "IMMU", "2403"], ["Infectious Diseases", "MEDI", "2725"]], "AuthorData": {"7005289543": {"Name": "Sansom D.M.", "AuthorID": "7005289543", "AffiliationID": "60032819, 60176023", "AffiliationName": "UCL Institute of Immunity and Transplantation, Royal Free Hospital"}, "7402359366": {"Name": "Walker L.S.K.", "AuthorID": "7402359366", "AffiliationID": "60032819, 60176023", "AffiliationName": "UCL Institute of Immunity and Transplantation, Royal Free Hospital"}}}